Printer Friendly

Wellbutrin XL.

GlaxoSmithKline's unique dual-acting treatment option for major depressive episodes, Wellbutrin, is currently available as a once daily extended-release tablet, Wellbutrin XL.

Wellbutrin XL helps patients to comply with therapy by a once daily dose. Wellbutrin XL once daily maintains bupropion plasma concentrations over 24 hours, helping to eliminate the evening peak in bupropion levels seen with Wellbutrin SR twice daily.

Wellbutrin XL once daily, with its unique action on noradrenaline and dopamine, targets residual symptoms of depression such as fatigue, low energy and low motivation. These symptoms are associated with poorer long-term clinical outcomes and can remain unresolved after antidepressant treatment.

Wellbutrin XL is not associated with serotonergic side-effects which may cause patients to discontinue therapy, such as sexual dysfunction, weight gain and somnolence.

Enquiries: GSK Customer Service, toll free on 0800 118 274.

References available on request.
COPYRIGHT 2008 South African Medical Association
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2008 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:South African Journal of Psychiatry
Article Type:Brief article
Geographic Code:6SOUT
Date:Dec 1, 2008
Previous Article:St John's Wort relieves symptoms of major depression.
Next Article:Pain, madness and the limits of medicine.

Related Articles
New Study Compared Sexual Functioning of Patients Treated with Wellbutrin XL(R) (bupropion HCl extended-release tablets) Versus Effexor XR(R)...
FDA Approves Wellbutrin XL(R) (bupropion HCI extended-release tablets) for the Prevention of Seasonal Major Depressive Episodes in Patients with a...
FDA clears generic Wellbutrin.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters